Elzbieta Jurkiewicz

Prof. Elzbieta Jurkiewicz

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2011 in European Journal of Paediatric Neurology
Verified
Journal Article
Open access
Sergiusz JóźwiakSergiusz Jóźwiak
Sergiusz Jóźwiak
KKKatarzyna Kotulska-Jóźwiak
Katarzyna Kotulska-Jóźwiak
DDDorota Domańska-Pakieła
Dorota Domańska-Pakieła
BŁBarbara Łojszczyk
Barbara Łojszczyk
MSMalgorzata Syczewska
Malgorzata Syczewska
MRMaria Respondek-Liberska
Maria Respondek-Liberska
Epilepsy appears in 70-80% of patients with tuberous sclerosis complex, most commonly in the first year of age. Early manifestation of epilepsy is associated with drug-resistant epilepsy and mental retardation in more than 80% of patients. Clinical epileptic seizures are preceded by deterioration of EEG recording thus infants with high risk of epilepsy can be identified. We hypothesized that preventative antiepileptic treatment of infants with multifocal activity on EEG might lower the incidence of drug-resistant epilepsy and mental retardation. Forty-five infants with early diagnosis of tuberous sclerosis complex were included in the open-label study. They were divided in two groups: standard (n=31) and preventative one (n=14). In standard group the antiepileptic treatment was launched early, but after the onset of seizures. In preventative group medication was commenced when active epileptic discharges were seen on EEG, but before the onset of clinical seizures. Children were followed till the end of 2 years of age. At 24 months of age mental retardation was significantly more frequent and severe in "standard" vs "preventative" group (48% vs 14%; p=0.031; mean IQ score 68.7 vs 92.3; p<0.05). The "preventative" group was characterized by higher ratio of seizure-free patients (93% vs 35%; p=0.004), lower incidence of drug-resistant epilepsy (7% vs 42%; p=0.021) and lower number of patients requiring polytherapy (21% vs 55%; 0.039) than the "standard group. Preventative antiepileptic treatment of infants with tuberous sclerosis complex and high risk of epilepsy markedly improves their neurodevelopmental outcome and reduces the incidence of drug-resistant seizures.

1 October 2011 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
MHMonika B. Hartig
Monika B. Hartig
AIArcangela Iuso
Arcangela Iuso
THTobias Haack
Tobias Haack
TKTomasz Kmiec
Tomasz Kmiec
EJElzbieta Jurkiewicz
Elzbieta Jurkiewicz
PHProkisch Holger
Prokisch Holger

12 June 2016 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
EPEwa Pronicka
Ewa Pronicka
DPDorota Piekutowska-Abramczuk
Dorota Piekutowska-Abramczuk
ECElżbieta Ciara
Elżbieta Ciara
JTJoanna Trubicka
Joanna Trubicka
DRDariusz Rokicki
Dariusz Rokicki
RPRafal Ploski
Rafal Ploski
Whole-exome sequencing (WES) has led to an exponential increase in identification of causative variants in mitochondrial disorders (MD). We performed WES in 113 MD suspected patients from Polish paediatric reference centre, in whom routine testing failed to identify a molecular defect. WES was performed using TruSeqExome enrichment, followed by variant prioritization, validation by Sanger sequencing, and segregation with the disease phenotype in the family. Likely causative mutations were identified in 67 (59.3 %) patients; these included variants in mtDNA (6 patients) and nDNA: X-linked (9 patients), autosomal dominant (5 patients), and autosomal recessive (47 patients, 11 homozygotes). Novel variants accounted for 50.5 % (50/99) of all detected changes. In 47 patients, changes in 31 MD-related genes (ACAD9, ADCK3, AIFM1, CLPB, COX10, DLD, EARS2, FBXL4, MTATP6, MTFMT, MTND1, MTND3, MTND5, NAXE, NDUFS6, NDUFS7, NDUFV1, OPA1, PARS2, PC, PDHA1, POLG, RARS2, RRM2B, SCO2, SERAC1, SLC19A3, SLC25A12, TAZ, TMEM126B, VARS2) were identified. The ACAD9, CLPB, FBXL4, PDHA1 genes recurred more than twice suggesting higher general/ethnic prevalence. In 19 cases, variants in 18 non-MD related genes (ADAR, CACNA1A, CDKL5, CLN3, CPS1, DMD, DYSF, GBE1, GFAP, HSD17B4, MECP2, MYBPC3, PEX5, PGAP2, PIGN, PRF1, SBDS, SCN2A) were found. The percentage of positive WES results rose gradually with increasing probability of MD according to the Mitochondrial Disease Criteria (MDC) scale (from 36 to 90 % for low and high probability, respectively). The percentage of detected MD-related genes compared with non MD-related genes also grew with the increasing MD likelihood (from 20 to 97 %). Molecular diagnosis was established in 30/47 (63.8 %) neonates and in 17/28 (60.7 %) patients with basal ganglia involvement. Mutations in CLPB, SERAC1, TAZ genes were identified in neonates with 3-methylglutaconic aciduria (3-MGA) as a discriminative feature. New MD-related candidate gene (NDUFB8) is under verification. We suggest WES rather than targeted NGS as the method of choice in diagnostics of MD in children, including neonates with 3-MGA aciduria, who died without determination of disease cause and with limited availability of laboratory data. There is a strong correlation between the degree of MD diagnosis by WES and MD likelihood expressed by the MDC scale.

29 January 2018 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
MSMonika Słowińska
Monika Słowińska
Sergiusz JóźwiakSergiusz Jóźwiak
Sergiusz Jóźwiak
Angela PeronAngela Peron
Angela Peron
JBJulita Borkowska
Julita Borkowska
DCDariusz Chmielewski
Dariusz Chmielewski
KKKatarzyna Kotulska-Jóźwiak
Katarzyna Kotulska-Jóźwiak
Tuberous sclerosis complex (TSC) is a genetic disorder with an incidence of 1:6000 live births and associated with the development of benign tumors in several organs. It is also characterized by high rates of neurological and neuropsychiatric abnormalities, including epilepsy affecting 70–90% of patients and being one of the major risk factors of intellectual disability. The first seizures in TSC patients appear usually between the 4th and the 6th months of life. Recent studies have shown the beneficial role of preventative antiepileptic treatment in TSC patients, with the possibility for improvement of cognitive outcome. Moreover, European recommendations suggest early introduction of Vigabatrin if ictal discharges occur on EEG recordings, with or without clinical manifestation. The aim of this study was to define the most useful approach to make the diagnosis of TSC before seizure onset (before age 4th months), in order to start early EEG monitoring with possible preventative treatment intervention. We performed a retrospective review of children who were suspected of having TSC due to single or multiple cardiac tumors as the first sign of the disease. We analyzed the medical records in terms of conducted clinical tests and TSC signs, which were observed until the end of the 4th month of age. Subsequently, we described the different clinical scenarios and recommendations for early diagnosis. 82/100 children were diagnosed with TSC within the first 4 months of life. Apart from cardiac tumors, the most frequently observed early TSC signs were subependymal nodules (71/100, 71%), cortical dysplasia (66/100, 66%), and hypomelanotic macules (35/100, 35%). The most useful clinical studies for early TSC diagnosis were brain magnetic resonance imaging (MRI), skin examination and echocardiography. Genetic testing was performed in 49/100 of the patients, but the results were obtained within the first 4 months of life in only 3 children. Early diagnosis of TSC, before seizure onset, is feasible and it is becoming pivotal for epilepsy management and improvement of cognitive outcome. Early TSC diagnosis is mostly based on clinical signs. Brain MRI, echocardiography, skin examination and genetic testing should be performed early in every patient suspected of having TSC.

23 August 2021 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
PDF file
MPMonika Prokop-Piotrkowska
Monika Prokop-Piotrkowska
KMKamila Marszałek-Dziuba
Kamila Marszałek-Dziuba
EMElżbieta Moszczyńska
Elżbieta Moszczyńska
MSMieczysław Szalecki
Mieczysław Szalecki
EJElzbieta Jurkiewicz
Elzbieta Jurkiewicz
Bone age is one of biological indicators of maturity used in clinical practice and it is a very important parameter of a child's assessment, especially in paediatric endocrinology. The most widely used method of bone age assessment is by performing a hand and wrist radiograph and its analysis with Greulich-Pyle or Tanner-Whitehouse atlases, although it has been about 60 years since they were published. Due to the progress in the area of Computer-Aided Diagnosis and application of artificial intelligence in medicine, lately, numerous programs for automatic bone age assessment have been created. Most of them have been verified in clinical studies in comparison to traditional methods showing good precision while eliminating inter- and intra-rater variability and reducing significantly the time of assessment. Also, there are available methods of assessment of bone age without X-ray exposure, like via ultrasound devices or MRI.

1 September 2013 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
KKKatarzyna Kotulska-Jóźwiak
Katarzyna Kotulska-Jóźwiak
DCDariusz Chmielewski
Dariusz Chmielewski
JBJulita Borkowska
Julita Borkowska
EJElzbieta Jurkiewicz
Elzbieta Jurkiewicz
DKDariusz Kuczyński
Dariusz Kuczyński
Sergiusz JóźwiakSergiusz Jóźwiak
Sergiusz Jóźwiak